1. Home
  2. RIGL vs MYN Comparison

RIGL vs MYN Comparison

Compare RIGL & MYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RIGL
  • MYN
  • Stock Information
  • Founded
  • RIGL 1996
  • MYN 1992
  • Country
  • RIGL United States
  • MYN United States
  • Employees
  • RIGL N/A
  • MYN N/A
  • Industry
  • RIGL Biotechnology: Pharmaceutical Preparations
  • MYN Finance Companies
  • Sector
  • RIGL Health Care
  • MYN Finance
  • Exchange
  • RIGL Nasdaq
  • MYN Nasdaq
  • Market Cap
  • RIGL 335.5M
  • MYN 358.2M
  • IPO Year
  • RIGL 2000
  • MYN N/A
  • Fundamental
  • Price
  • RIGL $38.85
  • MYN $9.31
  • Analyst Decision
  • RIGL Buy
  • MYN
  • Analyst Count
  • RIGL 5
  • MYN 0
  • Target Price
  • RIGL $38.20
  • MYN N/A
  • AVG Volume (30 Days)
  • RIGL 995.6K
  • MYN 86.0K
  • Earning Date
  • RIGL 08-05-2025
  • MYN 01-01-0001
  • Dividend Yield
  • RIGL N/A
  • MYN 4.12%
  • EPS Growth
  • RIGL N/A
  • MYN N/A
  • EPS
  • RIGL 5.43
  • MYN N/A
  • Revenue
  • RIGL $267,921,000.00
  • MYN N/A
  • Revenue This Year
  • RIGL $59.93
  • MYN N/A
  • Revenue Next Year
  • RIGL N/A
  • MYN N/A
  • P/E Ratio
  • RIGL $7.15
  • MYN N/A
  • Revenue Growth
  • RIGL 105.62
  • MYN N/A
  • 52 Week Low
  • RIGL $12.66
  • MYN $8.47
  • 52 Week High
  • RIGL $43.72
  • MYN $10.62
  • Technical
  • Relative Strength Index (RSI)
  • RIGL 68.57
  • MYN 48.18
  • Support Level
  • RIGL $39.00
  • MYN $9.20
  • Resistance Level
  • RIGL $42.08
  • MYN $9.33
  • Average True Range (ATR)
  • RIGL 2.32
  • MYN 0.07
  • MACD
  • RIGL -0.37
  • MYN -0.01
  • Stochastic Oscillator
  • RIGL 53.26
  • MYN 50.00

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

About MYN Blackrock MuniYield New York Quality Fund Inc.Common Stock

Blackrock Muniyield NY Quality FD, Inc is a closed-end management investment company. Its objective is to provide shareholders with a high level of current income exempt from federal income taxes. The Fund invests in long-term municipal obligations that are investment grade quality or are considered by the Fund's investment adviser to be of comparable quality, at the time of investment.

Share on Social Networks: